# DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment

> **NCT02504229** · PHASE2 · UNKNOWN · sponsor: **Beijing Biohealthcare Biotechnology Co.,Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **BIOLOGICAL:** autologous dendritic cells co-cultured with cytokine-induced killer cells
- **DRUG:** Gimeracil and Oteracil Porassium Capsules
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT02504229
- **Lead sponsor:** Beijing Biohealthcare Biotechnology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2018-07
- **Final completion:** —
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2015-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504229, "DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02504229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*